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In the current issue of Cardiology Journal,
Qi-ming Liu et al. [1] present the study in which they
prove that in the group of patients with microva-
scular angina (myocardial ischemia without steno-
sis in coronary arteries confirmed by means of se-
veral methods) more intense lipid disorders occur
than in the control group (precisely selected in
terms of gender and age) and additionally that it is
associated with endothelial function impairment.
This function was evaluated by measuring the
extent of flow mediated dilatation of brachial artery
(FMD, flow mediated dilatation). The negative
correlation between concentration of lipoprote-
in (a) and LDL cholesterol and FMD [1] was also
demonstrated.
This work touches upon the present questions
— the problem of microvascular angina pathogene-
sis, that is of syndrome X as well as the problem of
endothelial dysfunction and methods of its investi-
gation.
In patients with syndrome X among others the
following disorders were diagnosed: decreased den-
sity of capillary vessels in the myocardium [2], in-
creased blood viscosity [3], platelet aggregation di-
sorders [4], hormone disorders [5], abnormal reac-
tions of autonomous nervous system [6] and
variously expressed endothelial dysfunction [7].
Endothelial dysfunction is regarded as the first
stage in the development of atherosclerosis [8]. It
is not a local process, but it refers to all arterial
vessels. It was proved that all classical risk factors
can impair the function of endothelial [9–12]. In one
of our papers we demonstrated that endothelial dys-
function assessed with FMD intensifies with the
increasing number of co-existing atherosclerosis
risk factors [13].
Endothelial dysfunction is primarily associa-
ted with decrease of nitric oxide (NO) secretion
by endothelial cells, but also with the increase of
concentration of von Willebrand factor (vWF), en-
dothelin (ET), plasminogen activator inhibitor-1
(PAI-1) and with tPA (tissue plasminogen activa-
tor) concentration decrease [14]. This results in
reduced dilatation ability, predisposition to intrava-
scular thrombosis, leucocyte adhesion to vascular
wall, intense proliferation of smooth muscle cells
in tunica intima [9]. Since the credible measure-
ment of NO secretion is impossible because of its
instability, the research in order to find other me-
thods of endothelial function assessment was con-
ducted. For this evaluation could assess the con-
centration of other substances secreted by endothe-
lial cells. Endothelial-dependent dilatation of one of
easily accesible arteries, such as brachial artery, can
also be evaluated. Artery dilatation is caused by the
release of nitric oxide provoked by ‘shear stress’
generated by hyperemia which follows the manome-
ter cuff release. The latter method (FMD), as sim-
ple and easily repeatable, is accepted and recommen-
ded as the way of endothelial function assessment.
The Working Group was created for this method [15].
But so far standarization of the FMD research out-
comes and norms has not been achieved [16]. The
FMD values considered as reference oscillate in wide
range from 4 to 10% [16].
Until recently there was no research which
would demonstrate the correlation between concen-
tration of substances secreted by endothelium and
FMD. In one of the recently published papers Maas
et al. proved a direct relation between the decre-
ase of systemic NO production by endothelial NO
synthase (eNOS) and reduction of FMD [9]. In one
of our studies we documented that patients with
syndrome X have significantly higher PAI-1 con-
centrations than healthy people and patients with
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atypical chest pain. It was associated with a trend
towards lower FMD values [13]. The correlation be-
tween brachial artery FMD and extent and intensi-
ty of atherosclerotic alterations in coronary arteries
[10] was also confirmed.
In their study, Liu et al. [1] showed that in the
group of patients with microvascular angina, in com-
parison with control group, the levels of total cho-
lesterol (TC), LDL cholesterol, apolipoproteine B
and lipoproteine (a) were significantly higher and
were associated with FMD reduction. In the group
of patients with FMD values £ 4%, a significant ne-
gative correlation was observed between FMD and
concentration of LDL cholesterol and lipoprotein (a)
[1]. First studies describing endothelial dysfunction
in patients with hypercholesterolemia were publi-
shed in the late 90s [9]. Not all the studies later
conducted confirmed the existence of such rela-
tions. The mechanism in which hypercholesterole-
mia influences the decrease in production and/or
NO bioaccessibility is not clear. The following are
regarded as possible reasons: limited substrate,
that is L-arginine availability, increase in endoge-
nous eNOS inhibitors activity (ADMA, asymmetri-
cal dimethyloarginine), oxidative stress leading to
eNOS function impairment and negative influence of
free radicals [8]. In his work Maas et al. [9] showed
that secretion of 15N-labeled nitrate metabolites is
40% lower in patients with hypercholesterolemia
than in normocholesterolemic patients. It was con-
nected with 36% reduction of FMD and with consi-
derably lower eNOS expression in platelets [9]. Ho-
wever, this research showed no influence of chole-
sterol level on concentration of ADMA and
8-iso-PGF (prostaglandin F metabolite), which indi-
cates that increased oxidative stress cannot be con-
sidered the reason for reduced NO secretion. Ho-
wever, there are studies documenting that hypercho-
lesterolemia (LDL ≥ 160 mg/dL) contributes to the
enhacement of oxidative stress in advanced stages
of atherosclerosis.
The key role of eNOS in the development of
organ damage induced by hyperglycemia was pre-
sented on mice with homozygotic diabetes in rela-
tion to lack of eNOS [17]. It was stated that in indi-
viduals with diabetes the lack of eNOS has greater
adverse impact on microcirculation than on great
vessels — the alterations were observed in renal
glomerular vessels but not in the aorta. Despite
worse glycemia control, the changes in the ves-
sels were more benign in mice with diabetes, but
with eNOS preserved. In another study the influ-
ence of hyperglycemia and hyperinsulinemia on
dilatative vessel reaction was assessed. The outco-
mes of this study give the evidence that hypergly-
cemia and hyperinsulinemia increase oxidative
stress expressed through 5–10% reduction of pla-
sma antioxidants (in patients with diabetes as well
as in healthy individuals), which did not cause the
reduction of vasodilatative reaction in response to
acetylcholine [18]. So far the oxidative stress was
believed to play a key role in the development of
vessel complications in patients with diabetes. But
in one of the studies  conducted to date was proved
that the administration of rosiglitazone [a drug from
thiazolidinedione class of drugs which are PPAR-
-gamma receptor (peroxisome proliferator-activated
receptor gamma) agonists] brings the improvement
in endothelial function expressed with the increase
of FMD without any impact on ADMA and concen-
tration of oxidative stress markers [19]. Rosiglita-
zone was compared to glyburide (a derivative of sul-
phonylurea), which showed no influence on endothe-
lial function and oxidative stress markers in spite of
comparable to rosiglitazone influence on glycemia,
insulin concentration during fasting stomach and
concentration of peptide C. The favourable influen-
ce of thiazolidinediones, resulting most probably
from their pleiotropic effects, was confirmed in the
PROactive study, which showed a significant reduc-
tion in non-fatal myocardial infarction and stroke in-
cidence, with the trend towards the reduction of all-
cause mortality and reduction of number of cardio-
vascular events and interventions [20].
Endothelial dysfunction expressed with FMD
reduction and PAI-1 concentration increase was
documented in cigarette smokers [21]. In patients
with arterial hypertension a variously expressed
endothelial dysfunction was also diagnosed [22].
The division of the group (45 patients — 21
with microvascular angina and 24 healthy volunte-
ers) investigated by Liu et al. [1] into subgroups
with FMD £ 4% and FMD > 4% proved the signi-
ficant negative correlation between FMD £ 4% and
concentration of LDL cholesterol and Lp(a).
Patients with microvascular angina as well as pa-
tients without symptoms of angina were in the group
with lower FMD and higher concentration of LDL cho-
lesterol and Lp(a). It indicates that more advanced en-
dothelial dysfunction is not necessarily connected with
the presence of syndrome X. Therefore a question ari-
ses why microvascular angina does not occur in all pa-
tients with endothelial dysfunction since every patient
with microvascular angina has this dysfunction only
with the difference in its intensity? It suggests multi-
factorial pathogenesis of syndrome X. It is also unk-
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nown what extent of cardiovascular risk is associated
with this kind of myocardial ischemia?
It is clear that the evaluation of cardiovascular
risk based on classical atherosclerosis risk factors
occuring in a particular individual, especially in youn-
ger age groups, does not provide complete risk as-
sessment. That is why it is suggested to use the
FMD evaluation in combination with the IMT eva-
luation (evaluation of the thickness of the intima-
media complex in carotid artery) in order to complete
the assessment of the threat of cardiovascular events
[23]. The results of the research conducted by Qi-
ming Liu et al. imply the same.
It was demonstrated that endothelial dysfunc-
tion can improve after treatment with statins [24],
ACEI [25], some of the hypoglycemic drugs (irre-
spective of the glycemic control — rosiglitazone)
[19], after physical exercise [22, 26], smoking ces-
sation, supplementation with folic acid or vitamin C.
We should also expect that there will be further
studies searching for the links between endothelial
function enhancement and the improvement of the
myocardial perfusion together with subsiding of an-
ginal symptoms in patients with microvascular an-
gina after the therapy aiming to normalize an endo-
thelial function. Obviously if the endothelial dysfunc-
tion constitutes a pathogenetic basis for syndrome X
and is not only the ‘by-stander’ phenomenon, the mo-
dification of the lifestyle (physical activity) and ap-
plication of drugs which are known to improve en-
dothelial function should bring effects such as the im-
provement in FMD and clinical status as well as the
increase in myocardial perfusion proved by means
of different methods. The work by Liu et al. indica-
tes how many efforts should yet be made in order to
explain the pathogenesis of syndrome X, its diagno-
stics and treatment. It underlines also that we have
good diagnostic tools at our disposal and that they
should find wider use.
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